Miklaszewski, P.; Gadamer, A.M.; Janiszewska-Bil, D.; Lyssek-Boroń, A.; Dobrowolski, D.; Wylęgała, E.; Grabarek, B.O.; Koss, M.J.; Krysik, K.
Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT. Pharmaceuticals 2025, 18, 868.
https://doi.org/10.3390/ph18060868
AMA Style
Miklaszewski P, Gadamer AM, Janiszewska-Bil D, Lyssek-Boroń A, Dobrowolski D, Wylęgała E, Grabarek BO, Koss MJ, Krysik K.
Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT. Pharmaceuticals. 2025; 18(6):868.
https://doi.org/10.3390/ph18060868
Chicago/Turabian Style
Miklaszewski, Piotr, Anna Maria Gadamer, Dominika Janiszewska-Bil, Anita Lyssek-Boroń, Dariusz Dobrowolski, Edward Wylęgała, Beniamin Oskar Grabarek, Michael Janusz Koss, and Katarzyna Krysik.
2025. "Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT" Pharmaceuticals 18, no. 6: 868.
https://doi.org/10.3390/ph18060868
APA Style
Miklaszewski, P., Gadamer, A. M., Janiszewska-Bil, D., Lyssek-Boroń, A., Dobrowolski, D., Wylęgała, E., Grabarek, B. O., Koss, M. J., & Krysik, K.
(2025). Impact of Antiglaucoma Drug Number and Class on Corneal Epithelial Thickness Measured by OCT. Pharmaceuticals, 18(6), 868.
https://doi.org/10.3390/ph18060868
